Adapting to the Coronavirus Pandemic: Building and Incorporating a Diagnostic Pipeline in a Shared Resource Laboratory

Cytometry A. 2021 Jan;99(1):90-99. doi: 10.1002/cyto.a.24248. Epub 2020 Nov 22.

Abstract

In March 2020, with lockdown due to the coronavirus pandemic underway, the Francis Crick Institute (the Crick) regeared its research laboratories into clinical testing facilities. Two pipelines were established, one for polymerase chain reaction and the other for Serology. This article discusses the Cricks Flow Cytometry Science Technology Platform (Flow STP) role in setting up the Serology pipeline. Pipeline here referring to the overarching processes in place to facilitate the receipt of human sera through to a SARs-CoV-2 enzyme-linked immunosorbent assay result. We examine the challenges that had to be overcome by a research laboratory to incorporate clinical diagnostics and the processes by which this was achieved. It describes the governance required to run the service, the design of the standard operating procedures (SOPs) and pipeline, the setting up of the assay, the validation required to show the robustness of the pipeline and reporting the results of the assay. Finally, as the lockdown started to ease in June 2020, it examines how this new service affects the daily running of the Flow STP. © 2020 The Authors. Cytometry Part A published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry.

Keywords: Assay; Covid-19; Cytometry; Development; ELISA; Flow; Pipeline; SARs-CoV-2; SRL; Validation; clinical; pandemic; testing.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adaptation, Psychological*
  • COVID-19 / blood
  • COVID-19 / diagnosis*
  • COVID-19 / epidemiology
  • Enzyme-Linked Immunosorbent Assay / standards
  • Enzyme-Linked Immunosorbent Assay / trends
  • Flow Cytometry / standards*
  • Flow Cytometry / trends
  • Humans
  • Laboratories / standards*
  • Laboratories / trends
  • Reproducibility of Results
  • SARS-CoV-2 / isolation & purification*